- Home
- ANNX vs TERN Comparison
ANNX vs TERN Comparison
Compare ANNX & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- TERN
- Stock Information
- Founded
- ANNX 2011
- TERN 2017
- Country
- ANNX United States
- TERN United States
- Employees
- ANNX N/A
- TERN N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- ANNX Health Care
- TERN Health Care
- Exchange
- ANNX Nasdaq
- TERN Nasdaq
- Market Cap
- ANNX 362.4M
- TERN 298.1M
- IPO Year
- ANNX 2020
- TERN 2021
- Fundamental
- Price
- ANNX $1.93
- TERN $2.76
- Analyst Decision
- ANNX Strong Buy
- TERN Buy
- Analyst Count
- ANNX 7
- TERN 6
- Target Price
- ANNX $15.80
- TERN $18.30
- AVG Volume (30 Days)
- ANNX 1.7M
- TERN 917.8K
- Earning Date
- ANNX 03-03-2025
- TERN 03-20-2025
- Dividend Yield
- ANNX N/A
- TERN N/A
- EPS Growth
- ANNX N/A
- TERN N/A
- EPS
- ANNX N/A
- TERN N/A
- Revenue
- ANNX N/A
- TERN N/A
- Revenue This Year
- ANNX N/A
- TERN N/A
- Revenue Next Year
- ANNX N/A
- TERN N/A
- P/E Ratio
- ANNX N/A
- TERN N/A
- Revenue Growth
- ANNX N/A
- TERN N/A
- 52 Week Low
- ANNX $1.93
- TERN $2.75
- 52 Week High
- ANNX $7.85
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- ANNX 30.11
- TERN 30.05
- Support Level
- ANNX $2.18
- TERN $3.07
- Resistance Level
- ANNX $2.75
- TERN $3.72
- Average True Range (ATR)
- ANNX 0.25
- TERN 0.22
- MACD
- ANNX -0.01
- TERN -0.01
- Stochastic Oscillator
- ANNX 0.00
- TERN 1.03
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.